Greenbrook
Provides innovative, non-invasive treatments like Transcranial Magnetic Stimulation (TMS) and Spravato® for depression and OCD.
HQ location
Tysons, United States
Website
Launch date
Employees
Market cap
$2.1m
Enterprise value
$108m
Share price
$0.01 GBNH
Recent deals
loading funding rounds…
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 54 % | 68 % | 21 % | 21 % | 32 % | 7 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (14 %) | (21 %) | (18 %) | (26 %) | (31 %) | (28 %) | (39 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (17 %) | (23 %) | (45 %) | (69 %) | (47 %) | (89 %) | (66 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2 % | 2 % | 4 % | 1 % | 2 % | 1 % | - |
Source: Company filings or news article
Related Content
More about Greenbrook
EditGreenbrook TMS NeuroHealth is the nation’s leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and Obsessive Compulsive Disorder. Since 2011, we’ve provided more than 320,000 life-changing TMS treatments to over 9,000 patients. Learn more at greenbrooktms.com
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Greenbrook
Edit
ACQUISITION by Greenbrook Sep 2021
ACQUISITION by Greenbrook May 2022